Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis.

ABSTRACT:

Background

Recent clinical trials have shown that molecularly-guided treatments can improve survival in patients with cancers of unknown primary (CUP). However, the feasibility and clinical benefit of these treatments for CUP in a real-life setting remain uncertain. In France, a national multidisciplinary tumour board dedicated to patients with CUP (CUP MTB) was created in 2020, with the aims of coordinating pathological and molecular diagnostic analyses and providing a centralised expertise for therapeutic orientation. This study aimed at evaluating the diagnostic and therapeutic impact of the CUP MTB on patients with CUP in a national real-life setting.

Methods

Patient and tumour characteristics, treatments and outcomes are collected prospectively. This study reports the d

SUBMITTER: Dupain C 

PROVIDER: S-EPMC12639886 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature